Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seasonal influenza vaccination and immune competence during anti-PD-1 therapy in melanoma
2018-003616-49Phase 4Completed
- Sponsor
- Finnish Melanoma Group
- Start
- Oct 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of Vaxigrip in melanoma and influenza (2 arms), sponsored by Finnish Melanoma Group. Primary endpoint: Antibody titers against influenza virus. Started Oct 2018; status: completed.
02
Drugs
Vaxigrip
03
Conditions
melanomainfluenza
Beyond the preview
Go deeper on 2018-003616-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003616-49.